Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.27 – $3.34
19% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $32.5M | $52.1M | $113.9M | $133.7M | $198.6M | $169.7M | $183.2M | $223.9M |
| Cost of revenue | $16.5M | $26.4M | $67.0M | $60.5M | $74.8M | $79.2M | $77.8M | $119.5M |
| Gross profit | $16.0M | $25.6M | $46.9M | $73.2M | $123.8M | $90.5M | $105.4M | $104.4M |
| Gross margin | 49.2% | 49.2% | 41.2% | 54.8% | 62.3% | 53.3% | 57.5% | 46.6% |
| R&D | $37.1M | $40.5M | $48.6M | $76.0M | $64.8M | $103.8M | $98.9M | $97.7M |
| Operating income | −$62.2M | −$80.9M | −$73.1M | −$164.5M | −$98.5M | −$168.6M | −$152.3M | −$128.3M |
| EBITDA | −$55.2M | −$65.0M | −$55.1M | −$140.4M | −$65.8M | −$105.9M | −$93.1M | −$78.5M |
| Net income | −$53.1M | −$72.2M | −$61.2M | −$167.6M | −$91.0M | −$154.5M | −$146.2M | −$145.2M |
| Net margin | -163.3% | -138.7% | -53.8% | -125.4% | -45.8% | -91.1% | -79.8% | -64.9% |
| EPS (diluted) | -0.07 | -0.09 | -0.08 | -0.20 | -0.11 | -0.19 | -0.16 | -0.15 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $267M | $-0.11 | $-0.13–$-0.09 | 1 |
| 2027 | $326M | $-0.08 | $-0.09–$-0.07 | 1 |
| 2028 | $409M | $-0.02 | $-0.03–$-0.02 | 1 |
| 2029 | $495M | $0.01 | $0.01–$0.02 | 1 |
Forward consensus · source: Financial Modeling Prep
OXFORD NANOPORE TECH PLC
No one on the platform currently holds ONTTF.
No tracked institution reports a position in ONTTF as of their last filing.
No one on the platform has traded ONTTF yet.
| $2.0B |
| — |
| NURPFNeuren Pharmaceuticals Limited | $9.27 | +0.00% | $1.2B | — |
| PHMMFPharma Mar, S.A. | $79.49 | +0.00% | $1.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 3.7× sales vs its 13.8× historical median P/S.
Fair value ≈ $6.17 · price $1.66 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ONTTF Breakthrough genetic test diagnoses brain tumors in just two hours is based on Oxford Nanopore's devices and technology. To be rolled out across the UK's National Health Trusts. Source: https://bioengineer.org/breakthrough-genetic-test-diagnoses-brain-tumors-in-just-two-hours/
View on StockTwits ↗$ONTTF Seems like BGI Genomics is using nanopore tech now and will be the next big thing.. Oxford Nanopore just couldn’t convert and lost all momentum
View on StockTwits ↗$ONTTF I’m out. Too slow and too illiquid. Not going to attract proper institutional demand any time soon.
View on StockTwits ↗$ONTTF watching this… hoping itll start the explosive journey soon
View on StockTwits ↗$ONTTF Oxford Nanopore is going into the FTSE 250 according to FTSE Russell. They have also announced a partnership with UK Biobank for an "epigenetic dataset targeting the causes of cancer, dementia, complex disease." Financial backers of Biobank include Eric Schmidt and Ken Griffin. No impact on 2024, but supports the incremental revenue growth target of over 30% constant growth y-on-y between 2024 and 2027.
View on StockTwits ↗$ONTTF up 75% in the last six months, and nobody is talking or interested in this stock.
View on StockTwits ↗$ONTTF (Bloomberg) -- Oxford Nanopore shares climb as much as 4.2% after the British DNA-sequencing company said financial performance in the first-half of the year was in line with expectations. Analysts see Wednesday’s update alleviating concerns. ANALYST COMMENTARY Citi (buy) * The 1H revenue performance along with management commentary on improving growth trends is “somewhat better-than-expected,” analyst Veronika Dubajova writes in a note
View on StockTwits ↗$ONTTF Hopefully someone agrees with that and decides to take them over on the cheap.
View on StockTwits ↗@Franki5250 crazy how the once greats have fallen. Just goes to show that the genomics industry it’s way out of favor. Might just be a great buying opportunity for all three. $BNGO $PACB $ONTTF
View on StockTwits ↗$ONTTF listing on LSX was their biggest mistake
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.